- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NYRADA INC.: PROTECT-MI Phase IIa Clinical Trial Update No 3 | - | ASX | ||
| 12.10. | NYRADA INC.: Nyrada Receives Positive FDA Feedback | 2 | ASX | ||
| 12.10. | NYRADA INC.: Attaching Options Prospectus | - | ASX | ||
| 11.10. | NYRADA INC.: Securities Purchase Plan Offer Booklet | - | ASX | ||
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| 07.10. | NYRADA INC.: 2026 AGM Letter to Shareholders, Notice of Meeting & Proxy | - | ASX | ||
| 25.09. | NYRADA INC.: Cleansing Statement | 1 | ASX | ||
| 25.09. | NYRADA INC.: Application for quotation of securities - NYR | 1 | ASX | ||
| 21.09. | Nyrada Raises Fresh Capital to Fund Xolatryp Phase IIa And Pipeline Expansion | 2 | smallcaps.com.au | ||
| 21.09. | NYRADA INC.: Nyrada Successfully Raises AU$12.0 Million Via Placement | 1 | ASX | ||
| 21.09. | NYRADA INC.: Proposed issue of securities - NYR | 1 | ASX | ||
| 21.09. | NYRADA INC.: Proposed issue of securities - NYR | 2 | ASX | ||
| 21.09. | NYRADA INC.: Cap Raise Deck-Building the Future of TRPC-based Therapies | 1 | ASX | ||
| 21.09. | NYRADA INC.: Proposed issue of securities - NYR | 1 | ASX | ||
| 21.09. | NYRADA INC.: Proposed issue of securities - NYR | 1 | ASX | ||
| 17.09. | NYRADA INC.: Trading Halt | 1 | ASX | ||
| 16.09. | NYRADA INC.: Investor Presentation- Evans&Partners Small Cap Healthcare | 1 | ASX | ||
| 28.08. | NYRADA INC.: Change in substantial holding - M Azzi | 1 | ASX | ||
| 24.08. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 24.08. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 21.08. | Daily Special: Rural Funds Group, Nyrada, Liberty Metals, Noble Helium, Island Pharmaceuticals | 4 | Finance News Network |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,030 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| IMMUNOVANT | 26,730 | 0,00 % | Immunovant Q1 2027 Earnings Call: Complete Transcript | ||
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here's What You Should Know | ||
| PRAXIS PRECISION MEDICINES | 241,79 | +0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 37,320 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,950 | 0,00 % | HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | ||
| ERASCA | 13,375 | -0,11 % | Erasca drops after sacking COO | ||
| MODERNA | 193,00 | -0,52 % | Moderna-Aktie: +14% an einem Tag - was treibt den Kurs? | Moderna hat am Freitag einen der stärksten Handelstage des Jahres hingelegt. Die Aktie sprang um +14,2% auf 225 US$ und markierte damit gleichzeitig ein neues 52-Wochen-Hoch. Rückenwind kam von neuen... ► Artikel lesen | |
| COGENT BIOSCIENCES | 29,550 | +0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| NURIX THERAPEUTICS | 24,400 | 0,00 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,050 | +0,05 % | Tango Therapeutics, Inc.: Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 | ||
| TARSUS PHARMACEUTICALS | 68,06 | -0,01 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,840 | +0,07 % | Why Is Arcutis Biotherapeutics Stock Surging Thursday? | ||
| CITY THERAPEUTICS | 22,030 | -1,65 % | US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week's pricings | ||
| SUMMIT THERAPEUTICS | 14,650 | +0,14 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen |
NYRADA INC CDIS gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NYRADA INC CDIS finden Sie auf Wallstreet Online.